Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Deloitte
Argus Health
Harvard Business School
Chinese Patent Office
Medtronic
Merck
Julphar
US Department of Justice

Generated: November 13, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208610

« Back to Dashboard

NDA 208610 describes BAXDELA, which is a drug marketed by Melinta and is included in two NDAs. It is available from one supplier. There are thirteen patents protecting this drug. Additional details are available on the BAXDELA profile page.

The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this compound. Additional details are available on the delafloxacin meglumine profile page.
Summary for 208610
Tradename:BAXDELA
Applicant:Melinta
Ingredient:delafloxacin meglumine
Patents:8
Generic Entry Opportunity Date for 208610
Generic Entry Date for 208610*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208610
Ingredient-typeFluoroquinolones
Suppliers and Packaging for NDA: 208610
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BAXDELA delafloxacin meglumine TABLET;ORAL 208610 NDA Melinta Therapeutics, Inc 70842-101 70842-101-01 1 BOTTLE in 1 CARTON (70842-101-01) > 20 TABLET in 1 BOTTLE
BAXDELA delafloxacin meglumine TABLET;ORAL 208610 NDA Melinta Therapeutics, Inc 70842-101 70842-101-02 2 BLISTER PACK in 1 CARTON (70842-101-02) > 10 TABLET in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 450MG BASE
Approval Date:Jun 19, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 19, 2027
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:Jun 19, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Nov 20, 2027Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Teva
Fuji
Cipla
Julphar
Baxter
Mallinckrodt
Citi
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.